Earnings Summary

Inmune Bio Inc’s revenue fell -71.13% since last year same period to $0.03Mn in the Q4 2023. On a quarterly growth basis, Inmune Bio Inc has generated -34.88% fall in its revenue since last 3-months.

Inmune Bio Inc’s net profit fell -39.58% since last year same period to $-8.41Mn in the Q4 2023. On a quarterly growth basis, Inmune Bio Inc has generated 1.81% jump in its net profits since last 3-months.

Inmune Bio Inc’s net profit margin fell -383.53% since last year same period to -30028.57% in the Q4 2023. On a quarterly growth basis, Inmune Bio Inc has generated -50.79% fall in its net profit margins since last 3-months.

Inmune Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.54 - a -22.73% fall from last quarter’s estimates.

Inmune Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.54.

Inmune Bio Inc’s earning per share (EPS) fell -46.87% since last year same period to -0.47 in the Q4 2023. This indicates that the Inmune Bio Inc has generated -46.87% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inmune Bio Inc’s return on assets (ROA) stands at -0.27.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inmune Bio Inc’s return on equity (ROE) stands at -0.61.